Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)
Inflammatory Bowel Diseases · 18.08.2026
DOI: 10.1093/ibd/izag150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 18.08.2026. Verfasst von Shih-Hua Lin und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung…. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Real-world data on ustekinumab (UST) in Asian inflammatory bowel disease (IBD) populations remain limited. The T-RUST (Taiwan Multicenter Real-world Ustekinumab Study) study evaluated the effectiveness, durability, and safety of UST in patients with Crohn’s disease (CD) and ulcerative colitis (UC).
Methods
This retrospective multicenter study utilized data from the Taiwan Association for the Study of Intestinal Diseases IBD Registry between September 2019 and April 2025. Patients with CD or UC treated with UST were evaluated for clinical response and remission at weeks 4, 8, and 52. Subgroup analyses examined drug persistence according to biologic treatment history (biologic naive vs biologic experienced), prior advanced therapies, and difficult-to-treat IBD status. Fistula closure, endoscopic, radiologic, and histological remission, as well as safety outcomes, were assessed.
Results
A total of 379 patients were included, comprising 301 (79.4%) with CD and 78 (20.6%) with UC. Among patients with available week 52 data, clinical response was achieved in 183 (90.1%) of 203 CD patients and 40 (97.6%) of 41 UC patients. Corresponding clinical remission was achieved in 172 (84.7%) of 203 and 37 (90.2%) of 41 patients, respectively. Fistula closure was achieved in 17 (45.9%) of 37 patients with active fistulizing CD, including 10 (45.5%) of 22 patients with perianal fistulas. One-year UST persistence exceeded 80% in both cohorts, with persistence observed in 273 (91.0%) of 300 CD patients and 67 (85.9%) of 78 UC patients. UST was generally well tolerated, with no new safety signals identified.
Conclusions
UST demonstrated sustained effectiveness, meaningful fistula healing, and a favorable safety profile in this real-world IBD cohort. These findings support its role as a durable and well-tolerated therapeutic option in Asian clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation), New Taipei City 236, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
- Taiwan Association for the Study of Intestinal Diseases (TASID), Taoyuan City 333, Taiwan.
- Chang Gung Inflammatory Bowel Disease Center, Linkou, Taoyuan 333, Taiwan.
- Chang Gung Microbiota Therapy Center, Linkou, Taoyuan 333, Taiwan.
- Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou, Taoyuan 333, Taiwan.
ORCID-Profile: Shih-Hua Lin, Chiao-Hsiung Chuang, Chen-Wang Chang, Chen-Shuan Chung, Jen-Wei Chou, Tien-Yu Huang, Hsu-Heng Yen, Chung-Hsin Chang, Chi-Ming Tai, Wei-Chen Tai, Chih-Chien Yao, Yu-Bin Pan, Puo-Hsien Le
Zitieren
APA
Lin, S. H., Kuo, C. J., Chuang, C. H., Chang, C. W., Chung, C. S., Chou, J. W., Huang, T. Y., Yen, H. H., Tsai, T. J., Lin, C. P., Chang, C. H., Tai, C. M., Tai, W. C., Yao, C. C., Chen, C. C., Pan, Y. B., & Le, P. H. (2026). Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study). Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izag150
Vancouver
Lin SH, Kuo CJ, Chuang CH, Chang CW, Chung CS, Chou JW, et al. Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study). Inflammatory Bowel Diseases. 2026. doi:10.1093/ibd/izag150
BibTeX
@article{Lin2026,
author = {Lin, Shih-Hua and Kuo, Chia-Jung and Chuang, Chiao-Hsiung and Chang, Chen-Wang and Chung, Chen-Shuan and Chou, Jen-Wei and Huang, Tien-Yu and Yen, Hsu-Heng and Tsai, Tzung-Jiun and Lin, Ching-Pin and Chang, Chung-Hsin and Tai, Chi-Ming and Tai, Wei-Chen and Yao, Chih-Chien and Chen, Chih-Cheng and Pan, Yu-Bin and Le, Puo-Hsien},
title = {Effectiveness, Durability, and Safety of Ustekinumab in Inflammatory Bowel Disease: Results from the Taiwan Multicenter Real-world Ustekinumab Study (T-RUST Study)},
journal = {Inflammatory Bowel Diseases},
year = {2026},
doi = {10.1093/ibd/izag150}
}
EUVIMED